• Using Biomarkers to Determine Etiology, Predict Disease Course, and Target Therapy in Pediatric Pneumonia

  • 2023/09/12
  • 再生時間: 28 分
  • ポッドキャスト

Using Biomarkers to Determine Etiology, Predict Disease Course, and Target Therapy in Pediatric Pneumonia

  • サマリー

  • Drs Todd A. Florin and Lilliam Ambroggio discuss biomarkers in pediatric pneumonia, their potential to determine etiology and predict disease course, target therapy, and determine response to therapy.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987064). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Community-acquired Pneumonia in Children https://pubmed.ncbi.nlm.nih.gov/29932038/

    RSV Through the COVID-19 Pandemic: Burden, Shifting Epidemiology, and Implications for the Future https://pubmed.ncbi.nlm.nih.gov/36811330/

    Procalcitonin Use: Variation Across Hospitals and Trends Over Time https://pubmed.ncbi.nlm.nih.gov/34964049/

    The Management of Community-acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America https://pubmed.ncbi.nlm.nih.gov/21880587/

    A Three-step Diagnosis of Pediatric Pneumonia at the Emergency Department Using Clinical Predictors, C-reactive Protein, and Pneumococcal PCR https://pubmed.ncbi.nlm.nih.gov/28474099/

    A Prediction Model for Pediatric Radiographic Pneumonia https://pubmed.ncbi.nlm.nih.gov/34845493/

    Biomarkers and Disease Severity in Children With Community-acquired Pneumonia https://pubmed.ncbi.nlm.nih.gov/32404432/

    Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-acquired Pneumonia https://pubmed.ncbi.nlm.nih.gov/28158460/

    Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma Pneumoniae Community-acquired Pneumonia in Children https://pubmed.ncbi.nlm.nih.gov/31665253/

    Procalcitonin-guided Use of Antibiotics for Lower Respiratory Tract Infection https://pubmed.ncbi.nlm.nih.gov/29781385/

    Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower Respiratory Tract Infection in Children and Adolescents (ProPAED): A Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/23936304/

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Drs Todd A. Florin and Lilliam Ambroggio discuss biomarkers in pediatric pneumonia, their potential to determine etiology and predict disease course, target therapy, and determine response to therapy.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987064). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Community-acquired Pneumonia in Children https://pubmed.ncbi.nlm.nih.gov/29932038/

RSV Through the COVID-19 Pandemic: Burden, Shifting Epidemiology, and Implications for the Future https://pubmed.ncbi.nlm.nih.gov/36811330/

Procalcitonin Use: Variation Across Hospitals and Trends Over Time https://pubmed.ncbi.nlm.nih.gov/34964049/

The Management of Community-acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America https://pubmed.ncbi.nlm.nih.gov/21880587/

A Three-step Diagnosis of Pediatric Pneumonia at the Emergency Department Using Clinical Predictors, C-reactive Protein, and Pneumococcal PCR https://pubmed.ncbi.nlm.nih.gov/28474099/

A Prediction Model for Pediatric Radiographic Pneumonia https://pubmed.ncbi.nlm.nih.gov/34845493/

Biomarkers and Disease Severity in Children With Community-acquired Pneumonia https://pubmed.ncbi.nlm.nih.gov/32404432/

Procalcitonin Accurately Identifies Hospitalized Children With Low Risk of Bacterial Community-acquired Pneumonia https://pubmed.ncbi.nlm.nih.gov/28158460/

Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma Pneumoniae Community-acquired Pneumonia in Children https://pubmed.ncbi.nlm.nih.gov/31665253/

Procalcitonin-guided Use of Antibiotics for Lower Respiratory Tract Infection https://pubmed.ncbi.nlm.nih.gov/29781385/

Procalcitonin Guidance to Reduce Antibiotic Treatment of Lower Respiratory Tract Infection in Children and Adolescents (ProPAED): A Randomized Controlled Trial https://pubmed.ncbi.nlm.nih.gov/23936304/

Using Biomarkers to Determine Etiology, Predict Disease Course, and Target Therapy in Pediatric Pneumoniaに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。